Evaluation of Drug Resistance in the Tamoxifen-treated MKN-45 Gastric Cancer Cell Line via the Epithelial-mesenchymal

Zeinab Mahdian1,2, Mahdi Pouramir3,1, Hassan Akrami4

  • 1Department of Clinical Biochemistry, School of Medicine, Babol University of Medical Sciences, Babol, Iran.

Insights

Tamoxifen (TAM) overcomes 5-fluorouracil (5-FU) resistance in gastric cancer by suppressing epithelial-mesenchymal transition (EMT) and the TGFβ1/SMAD2 pathway. This strategy enhances chemotherapy effectiveness and induces apoptosis in cancer cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Multi-drug resistance (MDR) is a major challenge in gastric cancer (GC) chemotherapy.
  • Epithelial-mesenchymal transition (EMT), driven by TGFβ1/SMAD2, is crucial for MDR.
  • Tamoxifen (TAM) shows potential in overcoming MDR in GC.

Purpose of the Study:

  • To investigate TAM's effect on 5-FU resistance in GC.
  • To determine if TAM suppresses the TGFβ1/SMAD2 pathway and EMT.
  • To assess TAM's impact on apoptosis and gene expression in GC cells.

Main Methods:

  • Utilized the MKN-45 GC cell line.
  • Administered 5-FU, TAM, and combination treatments.
  • Assessed cytotoxicity (MTT assay), apoptosis (DNA laddering), and gene expression (real-time RT-PCR) of EMT markers (SNAI2, VIM, TGFβ1, SMAD2).

Main Results:

  • TAM significantly reduced the IC50 of 5-FU (P≤0.05).
  • Combined TAM and 5-FU treatment induced apoptosis in MKN-45 cells.
  • TAM and 5-FU inhibited TGFβ1 and EMT markers (VIM, SNAI2), reversing EMT and enhancing 5-FU sensitivity.

Conclusions:

  • TAM reverses EMT-mediated MDR by inhibiting the TGFβ1/SMAD2 pathway.
  • This suggests TAM is a potential therapeutic strategy to overcome 5-FU chemoresistance in GC.
  • Targeting EMT via TAM offers a novel approach for GC chemotherapy.